The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Epidemiology of Cardiac Amyloidosis–Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States
Open accessAbstract
Background: Cardiac amyloidosis is a substantially underdiagnosed disease, and contemporary estimates of the epidemiology of amyloidosis are lacking. This study aims to determine the incidence and prevalence of cardiac amyloidosis among Medicare beneficiaries from 2000 to 2012. Methods and Results: Medicare beneficiaries were counted in the prevalence cohort in each year they had (1) ≥1 principal or secondary International Classification of Diseases , Ninth Revision code for amyloidosis and (2) ≥1 principal or secondary International Classification of Diseases, Ninth Revision code for heart failure or cardiomyopathy within 2 years after the systemic amyloidosis code. A beneficiary was counted in the incidence cohort only during the first year in which they met criteria. Primary outcomes included the prevalence and incidence of hospitalizations for cardiac amyloidosis. There were 4746 incident cases of cardiac amyloidosis in 2012 and 15 737 prevalent cases in 2012. There was also a significant increase in the prevalence rate (8 to 17 per 100 000 person-years) and incidence rate (18 to 55 per 100 000 person-years) from 2000 to 2012, most notable after 2006. Incidence and prevalence increased substantially more among men, the elderly, and in blacks. Conclusions: The incidence and prevalence rates of cardiac amyloidosis are higher than previously thought. The incidence and prevalence rates of cardiac amyloidosis among hospitalized patients have increased since 2000, particularly among specific patient subgroups and after 2006, suggesting improved amyloidosis awareness and higher diagnostic rates with noninvasive imaging. In light of these trends, cardiac amyloidosis should be considered during the initial work up of patients ≥65 years old hospitalized with heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Kyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Pant, S., Patel, N. J., Deshmukh, A., Golwala, H., Patel, N., Badheka, A., Hirsch, G. A., & Mehta, J. L. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.518 · Cited by 604
Variant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black Americans
Jacobson, D. R., Pastore, R. D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F. S., & Buxbaum, J. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702133360703 · Cited by 554
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis
Maurer, M. S., Hanna, M., Grogan, M., Dispenzieri, A., Witteles, R., Drachman, B., Judge, D. P., Lenihan, D. J., Gottlieb, S. S., Shah, S. J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.596 · Cited by 538
Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
Maurer, M. S., Elliott, P., Comenzo, R., Semigran, M., & Rapezzi, C. (2017) · Circulation · doi:10.1161/circulationaha.116.024438 · Cited by 492
Left Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection Fraction
Mohammed, S. F., Mirzoyev, S. A., Edwards, W. D., Dogan, A., Grogan, D. R., Dunlay, S. M., Roger, V. L., Gertz, M. A., Dispenzieri, A., Zeldenrust, S. R., et al. (2014) · JACC: Heart Failure · doi:10.1016/j.jchf.2013.11.004 · Cited by 448
Epidemiology of AL amyloidosis: a real-world study using US claims data
Quock, T. P., Yan, T., Chang, E., Guthrie, S., & Broder, M. S. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016402 · Cited by 416
Muchtar, E., Gertz, M. A., Kumar, S. K., Lacy, M. Q., Dingli, D., Buadi, F. K., Grogan, M., Hayman, S. R., Kapoor, P., Leung, N., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751628 · Cited by 340
Cited by
How to Image Cardiac Amyloidosis
Dorbala, S., Cuddy, S., & Falk, R. H. (2020) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2019.07.015 · Cited by 308
Self-citationCost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
Kazi, D. S., Bellows, B. K., Baron, S. J., Shen, C., Cohen, D. J., Spertus, J. A., Yeh, R. W., Arnold, S. V., Sperry, B. W., Maurer, M. S., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.045093 · Cited by 263
Metadata
- Authors
- Gilstrap, L. G., Dominici, F., Wang, Y., El-Sady, M. S., Singh, A., Di Carli, M. F., Falk, R. H., & Dorbala, S.
- Venue
- Circulation: Heart Failure
- Published
- 2019-06
- Volume
- 12
- Issue
- 6
- Pages
- e005407-e005407
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W2952648944
- Cited by
- 260
- References
- 17
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epidemiology of Cardiac Amyloidosis–Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. https://app.cochat.ai/papers/10.1161/circheartfailure.118.005407
- The paper
- Gilstrap, L. G., Dominici, F., Wang, Y., El-Sady, M. S., Singh, A., Di Carli, M. F., Falk, R. H., & Dorbala, S. (2019). Epidemiology of Cardiac Amyloidosis–Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.118.005407
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.